Drug Database · Clinicians

Ustekinumab

Brands (2) Yesintek, StelaraShow all

Interleukin-12 Antagonist; Interleukin-23 Antagonist (Interleukin-12 Antagonists; Interleukin-23 Antagonists) US FDA class
Monoclonal antibody (interleukin-12 and interleukin-23 blockers); Interleukin inhibitors PH FDA category

Rx · Prescription drug6 PH products
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID c77a9664-e3bb-4023-b400-127aa53bca2b, version date September 8, 2026 (Stelara · Janssen Biotech, Inc.). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • Moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy.
  • Active psoriatic arthritis in adults and pediatric patients 6 years of age and older.
  • Moderately to severely active Crohn's disease in adults and pediatric patients 2 years of age and older.
  • Moderately to severely active ulcerative colitis in adults and pediatric patients 2 years of age and older.
US FDA label
Full indications and usage US FDA label

1 INDICATIONS AND USAGE STELARA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Moderate to severe plaque psoriasis in adults and pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy. (1.1) Active psoriatic arthritis in adults and pediatric patients 6 years of age and older.

(1.2) Moderately to severely active Crohn's disease in adults and pediatric patients 2 years of age and older. (1.3) Moderately to severely active ulcerative colitis in adults and pediatric patients 2 years of age and older. (1.4) 1.1 Plaque Psoriasis (PsO) STELARA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2 Psoriatic Arthritis (PsA) STELARA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3 Crohn's Disease (CD) STELARA is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active Crohn's disease. 1.4 Ulcerative Colitis (UC) STELARA is indicated for the treatment of adults and pediatric patients 2 years of age and older with moderately to severely active ulcerative colitis.

Contraindications

4 CONTRAINDICATIONS STELARA is contraindicated in patients with clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA [see Warnings and Precautions (5.5)]. Clinically significant hypersensitivity to any ustekinumab product or to any of the excipients in STELARA. (4)

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

Adult Patients with Plaque Psoriasis Subcutaneous Recommended Dosage (2.1): Weight Range (kilograms) Recommended Dosage less than or equal to 100 kg 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks greater than 100 kg 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks Pediatric Patients 6 Years of Age and Older with Plaque Psoriasis Subcutaneous Recommended Dosage (2.1): Weight-based dosing is recommended at the initial dose, 4 weeks later, then every 12 weeks thereafter. Weight Range (kilograms) Recommended Dose less than 60 kg 0.75 mg/kg 60 kg to 100 kg 45 mg greater than 100 kg 90 mg Psoriatic Arthritis Adult Subcutaneous Recommended Dosage (2.2): The recommended dosage is 45 mg administered subcutaneously initially and 4 weeks later, followed by 45 mg administered subcutaneously every 12 weeks.

For patients with co-existent moderate-to-severe plaque psoriasis weighing greater than 100 kg, the recommended dosage is 90 mg administered subcutaneously initially and 4 weeks later, followed by 90 mg administered subcutaneously every 12 weeks. Psoriatic Arthritis Pediatric Patients 6 Years of Age and Older Subcutaneous Recommended Dosage (2.2): Weight-based dosing is recommended at the initial dose, 4 weeks later, then …

2.1 Recommended Dosage in Plaque Psoriasis Subcutaneous Adult

2.1 Recommended Dosage in Plaque Psoriasis Subcutaneous Adult Dosage Regimen For patients weighing 100 kg or less, the recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For patients weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.

In subjects weighing more than 100 kg, 45 mg was also shown to be efficacious. However, 90 mg resulted in greater efficacy in these subjects [see Clinical Studies (14.1)]. Subcutaneous Pediatric Dosage Regimen Administer STELARA subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter. The recommended dose of STELARA for pediatric patients 6 years of age and older with plaque psoriasis based on body weight is shown below (Table 1).

Table 1: Recommended Dose of STELARA for Subcutaneous Injection in Pediatric Patients 6 Years of Age and Older With Plaque Psoriasis Body Weight of Patient at the Time of Dosing Recommended Dose less than 60 kg 0.75 mg/kg 60 kg to 100 kg 45 mg more than 100 kg 90 mg For pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate volume from the vial. Table 2: Injection Volumes of STELARA 45 mg/0.5 mL Vials for Pediatric Patients 6 Years of Age and Older With Plaque Psoriasis and Pediatric Patients 6 Years of Age and Older With Psoriatic Arthritis Refer to

2.2 Psoriatic Arthritis

2.2 Psoriatic Arthritis; Subcutaneous Pediatric Dosage Regimen. Weighing Less Than 60 kg Body Weight (kg) at the Time of Dosing Dose (mg) Volume of Injection (mL) 15 11.3 0.12 16 12 0.13 17 12.8 0.14 18 13.5 0.15 19 14.3 0.16 20 15 0.17 21 15.8 0.17 22 16.5 0.18 23 17.3 0.19 24 18 0.20 25 18.8 0.21 26 19.5 0.22 27 20.3 0.22 28 21 0.23 29 21.8 0.24 30 22.5 0.25 31 23.3 0.26 32 24 0.27 33 24.8 0.27 34 25.5 0.28 35 26.3 0.29 36 27 0.3 37 27.8 0.31 38 28.5 0.32 39 29.3 0.32 40 30 0.33 41 30.8 0.34 42 31.5 0.35 43 32.3 0.36 44 33 0.37 45 33.8 0.37 46 34.5 0.38 47 35.3 0.39 48 36 0.4 49 36.8 0.41 50 37.5 0.42 51 38.3 0.42 52 39 0.43 53 39.8 0.44 54 40.5 0.45 55 41.3 0.46 56 42 0.46 57 42.8 0.47 58 43.5 0.48 59 44.3 0.49

2.2 Recommended Dosage in Psoriatic Arthritis Subcutaneous Adult

2.2 Recommended Dosage in Psoriatic Arthritis Subcutaneous Adult Dosage Regimen The recommended dosage is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For patients with co-existent moderate-to-severe plaque psoriasis weighing more than 100 kg, the recommended dosage is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks.

Subcutaneous Pediatric Dosage Regimen Administer STELARA subcutaneously at Weeks 0 and 4, then every 12 weeks thereafter. The recommended dose of STELARA for pediatric patients 6 years of age and older with psoriatic arthritis, based on body weight, is shown below (Table 3). Table 3: Recommended Dose of STELARA for Subcutaneous Injection in Pediatric Patients 6 Years of Age and Older With Psoriatic Arthritis Body Weight of Patient at the Time of Dosing Recommended Dose less than 60 kg For pediatric patients weighing less than 60 kg, the administration volume for the recommended dose (0.75 mg/kg) is shown in Table 2; withdraw the appropriate volume from the vial. 0.75 mg/kg 60 kg or more 45 mg greater than 100 kg with co-existent moderate-to-severe plaque psoriasis 90 mg

2.3 Recommended Adult Dosage in Crohn's Disease Intravenous Induction Adult

2.3 Recommended Adult Dosage in Crohn's Disease Intravenous Induction Adult Dosage Regimen The recommended induction dosage is a single intravenous infusion using the weight-based dosage regimen specified in Table 4 [see Dosage and Administration (2.8)]. Table 4: Initial Intravenous Dose of STELARA in Adult Patients with Crohn's Disease Body Weight of Patient at the Time of Dosing Dose 55 kg or less 260 mg greater than 55 kg to 85 kg 390 mg greater than 85 kg 520 mg Subcutaneous Maintenance Adult Dosage Regimen The recommended maintenance dosage is a subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

2.4 Recommended Pediatric Dosage in Crohn's Disease Intravenous Induction

2.4 Recommended Pediatric Dosage in Crohn's Disease Intravenous Induction Pediatric Dosage Regimen The recommended induction dosage in pediatric patients weighing 10 kg and above is a single intravenous infusion using the weight-based dosage regimen specified in Table 5 [see Dosage and Administration (2.8)]. Table 5: Initial Intravenous Dose of STELARA in Pediatric Patients (Weighing 10 kg or More) with Crohn's Disease Body Weight of Patient at the Time of Dosing Dose 10 kg to 25 kg 10 mg/kg greater than 25 kg to 55 kg 260 mg greater than 55 kg to 85 kg 390 mg greater than 85 kg 520 mg Subcutaneous Maintenance Pediatric Dosage Regimen The recommended maintenance dosage in pediatric patients using weight-based dosing is: 10 kg to 35 kg: A subcutaneous 2.5 mg/kg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

Greater than 35 kg: A subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

2.5 Recommended Adult Dosage in Ulcerative Colitis Intravenous Induction Adult

2.5 Recommended Adult Dosage in Ulcerative Colitis Intravenous Induction Adult Dosage Regimen The recommended induction dosage is a single intravenous infusion using the weight-based dosage regimen specified in Table 6 [see Dosage and Administration (2.8)]. Table 6: Initial Intravenous Dosage of STELARA in Adult Patients with Ulcerative Colitis Body Weight of Patient at the Time of Dosing Dose 55 kg or less 260 mg greater than 55 kg to 85 kg 390 mg greater than 85 kg 520 mg Subcutaneous Maintenance Adult Dosage Regimen The recommended maintenance dosage is a subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

2.6 Recommended Pediatric Dosage in Ulcerative Colitis Intravenous Induction

2.6 Recommended Pediatric Dosage in Ulcerative Colitis Intravenous Induction Pediatric Dosage Regimen The recommended induction dosage in pediatric patients weighing 10 kg and above is a single intravenous infusion using the weight-based dosage regimen specified in Table 7 [see Dosage and Administration (2.8)]. Table 7: Initial Intravenous Dosage of STELARA in Pediatric Patients with Ulcerative Colitis Weighing 10 kg or More Body Weight of Patient at the Time of Dosing Dose 10 kg to 25 kg 10 mg/kg greater than 25 kg to 55 kg 260 mg greater than 55 kg to 85 kg 390 mg greater than 85 kg 520 mg Subcutaneous Maintenance Pediatric Dosage Regimen The recommended maintenance dosage in pediatric patients using weight-based dosing is: 10 kg to 35 kg: A subcutaneous 2.5 mg/kg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

Greater than 35 kg: A subcutaneous 90 mg dose administered 8 weeks after the initial intravenous dose, then every 8 weeks thereafter.

2.7 General Considerations for Administration

2.7 General Considerations for Administration STELARA is intended for use under the guidance and supervision of a healthcare provider. STELARA should only be administered to patients who will be closely monitored and have regular follow-up visits with a healthcare provider. The appropriate dose should be determined by a healthcare provider using the patient's current weight at the time of dosing.

In pediatric patients, it is recommended that STELARA be administered by a healthcare provider. If a healthcare provider determines that it is appropriate, a patient may self-inject or a caregiver may inject STELARA after proper training in subcutaneous injection technique. Instruct patients to follow the directions provided in the Instructions for Use [see Instructions for Use].

The needle cover on the prefilled syringe contains dry natural rubber (a derivative of latex). The needle cover should not be handled by persons sensitive to latex. It is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated.

When using the vial, a 1 mL syringe with a 27 gauge, ½ inch needle is recommended. Prior to administration, visually inspect STELARA for particulate matter and discoloration. STELARA is a colorless to light yellow solution and may contain a few small translucent or white particles. Do not use STELARA if it is discolored or cloudy, or if other particulate matter is present.

STELARA does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe.

2.8 Preparation and Administration

2.8 Preparation and Administration of STELARA 130 mg/26 mL (5 mg/mL) Vial for Intravenous Infusion (Crohn's Disease and Ulcerative Colitis) STELARA solution for intravenous infusion must be diluted, prepared, and infused by a healthcare professional using aseptic technique. Calculate the dose and the number of STELARA vials needed based on patient weight (see Table 4, Table 5, Table 6, and Table 7 above).

Obtain the appropriate infusion solution (Table 8). Withdraw and discard a volume of the infusion solution equal to the volume of STELARA solution to be added: Table 8: Appropriate Infusion Solution and Final Infusion Volumes for Intravenous Infusion of STELARA Solution Patient Population Body Weight of Patient at the Time of Dosing Infusion Solution Final Volume in the Infusion Bag Pediatric 10 kg to 25 kg 0.9% Sodium Chloride Injection 100 mL Remove a volume of infusion solution equal to the volume of STELARA solution to be added to obtain the final volume.

Greater than 25 kg 0.9% Sodium Chloride Injection 250 mL Adult All weights 0.45% or 0.9% Sodium Chloride Injection 250 mL Add the volume of STELARA solution equal to the calculated dose of STELARA to the infusion solution and gently mix. Visually inspect the diluted solution before infusion. Do not use if visibly opaque particles, discoloration or foreign particles are observed.

Infuse the diluted solution over a period of at least one hour. Once diluted, the infusion should be completely administered within the storage time (see Storage below). Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer). Do not infuse STELARA concomitantly in the same intravenous line with other agents.

STELARA does not contain preservatives. Each vial is for a one-time use in only one patient. Discard any remaining solution. Dispose any unused medicinal product in accordance with local requirements. Discard any unused portion of the infusion solution. Storage Do not freeze. Storage time at room temperature begins once the diluted solution has been prepared. 100 mL infusion bag: If necessary, the diluted infusion solution may be kept at room temperature up to 25 °C (77 °F) for up to 3 hours.

The infusion should be completed within 4 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period). 250 mL infusion bag: If necessary, the diluted infusion solution may be kept at room temperature up to 25 °C (77 °F) for up to 7 hours. The infusion should be completed within 8 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period).

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

8.4 Pediatric Use Plaque Psoriasis The safety and effectiveness of STELARA have been established for the treatment of moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for phototherapy or systemic therapy. Use of STELARA in pediatric patients 12 to less than 17 years of age is supported by evidence from a multicenter, randomized, 60 week trial (Ps STUDY 3) that included a 12 week, double-blind, placebo-controlled, parallel group portion, in 110 pediatric subjects 12 years of age and older [see Adverse Reactions (6.1) and Clinical Studies (14.2)].

Use of STELARA in pediatric patients 6 to 11 years of age is supported by evidence from an open-label, single-arm, efficacy, safety, and pharmacokinetics trial (Ps STUDY 4) in 44 subjects [see Adverse Reactions (6.1) and Clinical Pharmacology (12.3)]. The safety and effectiveness of STELARA have not been established in pediatric patients less than 6 years of age with plaque psoriasis.

Psoriatic Arthritis The safety and effectiveness of STELARA have been established for treatment of psoriatic arthritis in pediatric patients 6 years of age and older. Use of STELARA in these age groups is supported by evidence from adequate and well controlled trials of STELARA in adult subjects with psoriasis and PsA, pharmacokinetic data from adult subjects with psoriasis, adult subjects with PsA and pediatric subjects with psoriasis, and safety data from two clinical trials in 44 pediatric subjects 6 to 11 years old with psoriasis and 110 pediatric subjects 12 years of age and older with psoriasis.

The observed pre-dose (trough) concentrations are generally comparable between adult subjects with psoriasis, adult subjects with PsA and pediatric subjects with psoriasis, and the PK exposure is expected to be comparable between adult and pediatric subjects with PsA [see Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1, 14.2, 14.3)]. The safety and effectiveness of STELARA have not been established in pediatric patients less than 6 years old with psoriatic arthritis.

Crohn's Disease The safety and effectiveness of STELARA have been established for the treatment of moderately to severely active Crohn's disease in pediatric patients aged 2 years and older. Use of STELARA for this indication is supported by evidence from adequate and well-controlled studies in adults with additional safety, efficacy, and pharmacokinetic data from a 52-week study in 101 pediatric subjects aged 2 to 17 years of age.

The adverse reaction profile in these pediatric subjects was similar to adverse reactions reported in the clinical trials of adults with Crohn's disease. Other adverse reactions reported in at least 10% of pediatric subjects were upper respiratory tract infection (13% during induction and 17% during maintenance), COVID-19 (17% during maintenance), and headache (10% during maintenance) [see Warnings and Precautions (5.1), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.4, 14.5)].

The safety and effectiveness of STELARA for the treatment of moderately to severely active Crohn's disease have not been established in pediatric patients less than 2 years of age. Ulcerative Colitis The safety and effectiveness of STELARA have been established for the treatment of moderately to severely active ulcerative colitis in pediatric patients aged 2 years and older.

Use of STELARA for this indication is supported by evidence from adequate and well-controlled studies in adult subjects with ulcerative colitis, pharmacokinetic and safety data from pediatric subjects with Crohn's disease aged 2 to 17 years of age, and additional safety, efficacy, and pharmacokinetic data from a 52-week study in 112 pediatric subjects with ulcerative colitis aged 3 to 17 years of age. The adverse reaction profile in the pediatric subjects with ulcerative colitis was similar to adverse reactions reported in the clinical trials of adults with ulcerative colitis.

One pediatric subject experienced worsening of preexisting peripheral neuropathy during treatment with STELARA, resulting in hospitalization [see Warnings and Precautions (5.1), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14.6, 14.7)]. The safety and effectiveness of STELARA for the treatment of moderately to severely active ulcerative colitis have not been established in pediatric patients less than 2 years of age.

Dosing: Older adult

Geriatric use (US label) US FDA label

8.5 Geriatric Use Of the 6709 subjects exposed to STELARA, a total of 340 were 65 years of age or older (183 subjects with plaque psoriasis, 65 subjects with psoriatic arthritis, 58 subjects with Crohn's disease, and 34 subjects with ulcerative colitis), and 40 subjects were 75 years of age or older. Clinical trials of STELARA did not include sufficient numbers of subjects 65 years of age and older to determine whether they respond differently from younger adult subjects.

Administration

2.7 General Considerations for Administration STELARA is intended for use under the guidance and supervision of a healthcare provider. STELARA should only be administered to patients who will be closely monitored and have regular follow-up visits with a healthcare provider. The appropriate dose should be determined by a healthcare provider using the patient's current weight at the time of dosing. In pediatric patients, it is recommended that STELARA be administered by a healthcare provider. If a healthcare provider determines that it is appropriate, a patient may self-inject or a caregiver may inject STELARA after proper training in subcutaneous injection technique. Instruct patients to follow the directions provided in the Instructions for Use [see Instructions for Use] . The needle cover on the prefilled syringe contains dry natural rubber (a derivative of latex). The needle cover should not be handled by persons sensitive to latex. It is recommended that each injection be administered at a different anatomic location (such as upper arms, gluteal regions, thighs, or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, or indurated. When using the vial, a 1 mL syringe with a 27 gauge, ½ inch needle is recommended. Prior to administration, visually inspect STELARA for particulate matter and discoloration. STELARA is a colorless to light yellow solution and may contain a few small translucent or white particles. Do not use STELARA if it is discolored or cloudy, or if other particulate matter is present. STELARA does not contain preservatives; therefore, discard any unused product remaining in the vial and/or syringe.

2.8 Preparation and Administration of STELARA 130 mg/26 mL (5 mg/mL) Vial for Intravenous Infusion (Crohn's Disease and Ulcerative Colitis) STELARA solution for intravenous infusion must be diluted, prepared, and infused by a healthcare professional using aseptic technique. Calculate the dose and the number of STELARA vials needed based on patient weight (see Table 4 , Table 5 , Table 6 , and Table 7 above). Obtain the appropriate infusion solution (Table 8). Withdraw and discard a volume of the infusion solution equal to the volume of STELARA solution to be added: Table 8: Appropriate Infusion Solution and Final Infusion Volumes for Intravenous Infusion of STELARA Solution Patient Population Body Weight of Patient at the Time of Dosing Infusion Solution Final Volume in the Infusion Bag Pediatric 10 kg to 25 kg 0.9% Sodium Chloride Injection 100 mL Remove a volume of infusion solution equal to the volume of STELARA solution to be added to obtain the final volume. Greater than 25 kg 0.9% Sodium Chloride Injection 250 mL Adult All weights 0.45% or 0.9% Sodium Chloride Injection 250 mL Add the volume of STELARA solution equal to the calculated dose of STELARA to the infusion solution and gently mix. Visually inspect the diluted solution before infusion. Do not use if visibly opaque particles, discoloration or foreign particles are observed. Infuse the diluted solution over a period of at least one hour. Once diluted, the infusion should be completely administered within the storage time (see Storage below) . Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 0.2 micrometer). Do not infuse STELARA concomitantly in the same intravenous line with other agents. STELARA does not contain preservatives. Each vial is for a one-time use in only one patient. Discard any remaining solution. Dispose any unused medicinal product in accordance with local requirements. Discard any unused portion of the infusion solution. Storage Do not freeze. Storage time at room temperature begins once the diluted solution has been prepared. 100 mL infusion bag : If necessary, the diluted infusion solution may be kept at room temperature up to 25 °C (77 °F) for up to 3 hours. The infusion should be completed within 4 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period). 250 mL infusion bag : If necessary, the diluted infusion solution may be kept at room temperature up to 25 °C (77 °F) for up to 7 hours. The infusion should be completed within 8 hours after the dilution in the infusion bag (cumulative time after preparation including the storage and the infusion period).

US FDA label

Dosage forms

Philippines

  • Solution for injection: 45 mg/0.5 mL, 90 mg/mL
  • ) solution for injection: 130 mg/26 mL (5 mg/mL

Registered products in the Philippines

6 products registered with the Food and Drug Administration (FDA) Philippines list Ustekinumab as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products6
Philippine FDA-registered products for Ustekinumab
Package insert
StelaraUstekinumab
45 mg/0.5 mL Solution For Injection (SC)0.5 mL in 2 mL Type I glass vial with butyl rubber stopper and aluminum seal with light-green flip-off button (Box of 1's)
Rx
Cilag AGSwitzerland
Johnson & Johnson (Philippines), Inc.
BR-1415
Aug 31, 2027
StelaraUstekinumab
90 mg/mL Solution for Injection (SC)Single dose. 1 mL Pre-filled glass syringe with a fixed 27G, half-inch needle and needle cover (Box of 1's)
Rx
Cilag AGSwitzerland
JOHNSON & JOHNSON (PHILIPPINES), INC.
BR-983
Oct 14, 2029
YesintekUstekinumab
130 mg/ 26 mL (5 mg/mL) Solution For Injection (IV)26 mL-net content in 30 mL Type-I glass vial with gray chlorobutyl rubber stopper, sealed with aluminum overseal and plastic flip-off component (Box of 1's)
Rx
Biocon Biologicals LimitedIndia
Biocon Biologics Philippines Inc.
BR-1515
Oct 1, 2031
YesintekUstekinumab
45 mg/ 0.5ml Solution For Injection (SC)0.5 mL-net content in 2 mL Type-I glass vial with gray chlorobutyl rubber stopper, sealed with aluminum overseal and plastic flip-off component (Box of 1's)
Rx
Biocon Biologicals LimitedIndia
Biocon Biologics Philippines Inc.
BR-1513
Oct 1, 2031
YesintekUstekinumab
45 mg/0.5ml Solution For Injection0.5 mL Type I glass pre-filled syringe with bromobutyl plunger stopper, and assembled with polypropylene plunger rod, 29Gx1/2" hypodermic sainless-steel needle, rigid needle shield and needle safety guard (Box of 1's)
Rx
Biocon Biologics Limited
Biocon Biologic Philippines Inc.
BR-1512
Oct 1, 2031
YesintekUstekinumab
90 mg/mL Solution For Injection1 mL Type I glass pre-filled syringe with bromobutyl plunger stopper, and assembled with polupropylene plunger rod, 29Gx1/2" hypodermic sainless-steel needle, rigid needle shield and needle safety guard (Box of 1's)
Rx
Biocon Biologics LimitedIndia
Biocon Biologic Philippines Inc.
BR-1514
Oct 1, 2031

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

United States (label)

Dosage forms and strengths (US label) US FDA label

3 DOSAGE FORMS AND STRENGTHS STELARA (ustekinumab) is a colorless to light yellow solution and may contain a few small translucent or white particles. Subcutaneous Injection Injection: 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe Injection: 45 mg/0.5 mL solution in a single-dose vial Intravenous Infusion Injection: 130 mg/26 mL (5 mg/mL) solution in a single-dose vial Subcutaneous Injection (3) Injection: 45 mg/0.5 mL or 90 mg/mL solution in a single-dose prefilled syringe Injection: 45 mg/0.5 mL solution in a single-dose vial Intravenous Infusion (3) Injection: 130 mg/26 mL (5 mg/mL) solution in a single-dose vial

Warnings/Precautions

Warnings and precautions (US label) US FDA label
  • Infections: Serious infections have occurred. Avoid starting STELARA during any clinically important active infection. If a serious infection or clinically significant infection develops, discontinue STELARA until the infection resolves. (5.1)
  • Theoretical Risk for Particular Infections: Serious infections from mycobacteria, salmonella, and Bacillus Calmette-Guerin (BCG) vaccinations have been reported in patients genetically deficient in IL-12/IL-23. Consider diagnostic tests for these infections as dictated by clinical circumstances. (5.2)
  • Tuberculosis (TB): Evaluate patients for TB prior to initiating treatment with STELARA. Initiate treatment of latent TB before administering STELARA. (5.3)
  • Malignancies: STELARA may increase risk of malignancy. The safety of STELARA in patients with a history of or a known malignancy has not been evaluated. (5.4)
  • Serious Hypersensitivity Reactions: If a severe or other clinically significant hypersensitivity reaction occurs, discontinue STELARA immediately and initiate appropriate medical treatment. (5.5)
  • Posterior Reversible Encephalopathy Syndrome (PRES): If PRES is suspected, treat promptly, and discontinue STELARA. (5.6)
  • Immunizations: Avoid use of live vaccines in patients during treatment with STELARA. (5.7)
  • Noninfectious Pneumonia: Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic …
5.1 Infections

5.1 Infections STELARA may increase the risk of infections and reactivation of latent infections. Serious bacterial, mycobacterial, fungal, and viral infections were observed in patients receiving STELARA [see Adverse Reactions (6.1, 6.2)]. Serious infections requiring hospitalization, or otherwise clinically significant infections, reported in clinical trials included the following: Plaque Psoriasis: diverticulitis, cellulitis, pneumonia, appendicitis, cholecystitis, sepsis, osteomyelitis, viral infections, gastroenteritis, and urinary tract infections.

Psoriatic arthritis: cholecystitis. Crohn's disease in adults: anal abscess, gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeria meningitis. Crohn's disease in pediatrics: Aeromonas gastroenteritis. Ulcerative colitis in adults: gastroenteritis, ophthalmic herpes zoster, pneumonia, and listeriosis. Ulcerative colitis in pediatrics: salmonellosis and cytomegalovirus.

Avoid initiating treatment with STELARA in patients with any clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to initiating use of STELARA in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur while on treatment with STELARA and discontinue STELARA for serious or clinically significant infections until the infection resolves or is adequately treated.

5.2 Theoretical Risk for Vulnerability to Particular Infections

5.2 Theoretical Risk for Vulnerability to Particular Infections Individuals genetically deficient in IL-12/IL-23 are particularly vulnerable to disseminated infections from mycobacteria (including nontuberculous, environmental mycobacteria), salmonella (including nontyphi strains), and Bacillus Calmette-Guerin (BCG) vaccinations. Serious infections and fatal outcomes have been reported in such patients.

It is not known whether patients with pharmacologic blockade of IL-12/IL-23 from treatment with STELARA may be susceptible to these types of infections. Consider appropriate diagnostic testing, (e.g., tissue culture, stool culture, as dictated by clinical circumstances).

5.3 Pre-treatment Evaluation for Tuberculosis

5.3 Pre-treatment Evaluation for Tuberculosis Evaluate patients for tuberculosis infection prior to initiating treatment with STELARA. Avoid administering STELARA to patients with active tuberculosis infection. Initiate treatment of latent tuberculosis prior to administering STELARA. Consider anti-tuberculosis therapy prior to initiation of STELARA in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.

Closely monitor patients receiving STELARA for signs and symptoms of active tuberculosis during and after treatment.

5.4 Malignancies

5.4 Malignancies STELARA is an immunosuppressant and may increase the risk of malignancy. Malignancies were reported among subjects who received STELARA in clinical trials [see Adverse Reactions (6.1)]. In rodent models, inhibition of IL-12/IL-23p40 increased the risk of malignancy [see Nonclinical Toxicology (13.1)]. The safety of STELARA has not been evaluated in patients who have a history of malignancy or who have a known malignancy.

There have been post-marketing reports of the rapid appearance of multiple cutaneous squamous cell carcinomas in patients receiving STELARA who had pre-existing risk factors for developing non-melanoma skin cancer. Monitor all patients receiving STELARA for the appearance of non-melanoma skin cancer. Closely follow patients greater than 60 years of age, those with a medical history of prolonged immunosuppressant therapy and those with a history of PUVA treatment [see Adverse Reactions (6.1)].

5.5 Serious Hypersensitivity Reactions

5.5 Serious Hypersensitivity Reactions Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with STELARA in clinical trials and postmarketing. Some serious hypersensitivity reactions have occurred during the first intravenous dose of STELARA [see Adverse Reactions (6.1, 6.2)]. If a severe or clinically significant hypersensitivity reaction occurs, discontinue STELARA immediately and initiate appropriate medical treatment [see Contraindications (4)].

5.6 Posterior Reversible Encephalopathy Syndrome (PRES)

5.6 Posterior Reversible Encephalopathy Syndrome (PRES) Two cases of posterior reversible encephalopathy syndrome (PRES), also known as Reversible Posterior Leukoencephalopathy Syndrome (RPLS), were reported in clinical trials. Cases have also been reported in postmarketing experience in patients with psoriasis, psoriatic arthritis, and Crohn's disease.

Clinical presentation included headaches, seizures, confusion, visual disturbances, and imaging changes consistent with PRES a few days to several months after ustekinumab initiation. A few cases reported latency of a year or longer. Patients recovered with supportive care following withdrawal of ustekinumab. Monitor all patients treated with STELARA for signs and symptoms of PRES.

If PRES is suspected, promptly administer appropriate treatment and discontinue STELARA.

5.7 Immunizations

5.7 Immunizations Prior to initiating therapy with STELARA, patients should receive all age-appropriate immunizations as recommended by current immunization guidelines. Patients being treated with STELARA should avoid receiving live vaccines. Avoid administering BCG vaccines during treatment with STELARA or for one year prior to initiating treatment or one year following discontinuation of treatment.

Caution is advised when administering live vaccines to household contacts of patients receiving STELARA because of the potential risk for shedding from the household contact and transmission to patient. Non-live vaccinations received during a course of STELARA may not elicit an immune response sufficient to prevent disease.

5.8 Noninfectious Pneumonia

5.8 Noninfectious Pneumonia Cases of interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia have been reported during post-approval use of STELARA. Clinical presentations included cough, dyspnea, and interstitial infiltrates following one to three doses. Serious outcomes have included respiratory failure and prolonged hospitalization.

Patients improved with discontinuation of therapy and in certain cases administration of corticosteroids. If diagnosis is confirmed, discontinue STELARA and institute appropriate treatment [see Adverse Reactions (6.2)].

Drug interactions

Drug interactions (US label) US FDA label
7.1 Concomitant Therapies

7.1 Concomitant Therapies In trials in subjects with plaque psoriasis the safety of STELARA in combination with immunosuppressive agents or phototherapy has not been evaluated. In trials in subjects with psoriatic arthritis, concomitant MTX use did not appear to influence the safety or efficacy of STELARA. In trials in subjects with Crohn's disease (CD-1 and CD-2) and ulcerative colitis (UC-1), immunomodulators (6-MP, AZA, MTX) were used concomitantly in approximately 30% of subjects and corticosteroids were used concomitantly in approximately 40% and 50% of Crohn's disease and ulcerative colitis subjects, respectively.

Use of these concomitant therapies did not appear to influence the overall safety or efficacy of STELARA.

7.2 CYP450 Substrates

7.2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e.g., IL-1, IL-6, TNFα, IFN) during chronic inflammation. Thus, use of STELARA, an antagonist of IL-12 and IL-23, could normalize the formation of CYP450 enzymes. Upon initiation or discontinuation of STELARA in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.

See the prescribing information of specific CYP substrates. A CYP-mediated drug interaction effect was not observed in subjects with Crohn's disease [see Clinical Pharmacology (12.3)].

7.3 Allergen Immunotherapy

7.3 Allergen Immunotherapy STELARA has not been evaluated in patients who have undergone allergy immunotherapy. STELARA may decrease the protective effect of allergen immunotherapy (decrease tolerance) which may increase the risk of an allergic reaction to a dose of allergen immunotherapy. Therefore, caution should be exercised in patients receiving or who have received allergen immunotherapy, particularly for anaphylaxis.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Drug Interaction Studies The effects of IL-12 or IL-23 on the regulation of CYP450 enzymes were evaluated in an in vitro study using human hepatocytes, which showed that IL-12 and/or IL-23 at levels of 10 ng/mL did not alter human CYP450 enzyme activities (CYP1A2, 2B6, 2C9, 2C19, 2D6, or 3A4).

No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), dextromethorphan (CYP2D6 substrate), or midazolam (CYP3A substrate) were observed when used concomitantly with ustekinumab at the approved recommended dosage in subjects with Crohn's disease [see Drug Interactions (7.2) ] .

Use of these concomitant therapies did not appear to influence the overall safety or efficacy of STELARA. 7.2 CYP450 Substrates The formation of CYP450 enzymes can be suppressed by increased levels of certain cytokines (e.g., IL-1, IL-6, TNFα, IFN) during chronic inflammation.

Thus, use of STELARA, an antagonist of IL-12 and IL-23, could normalize the formation of CYP450 enzymes.

Upon initiation or discontinuation of STELARA in patients who are receiving concomitant CYP450 substrates, particularly those with a narrow therapeutic index, consider monitoring for therapeutic effect or drug concentration and adjust the individual dosage of the CYP substrate as needed.

Adverse reactions

Adverse reactions (US label) US FDA label
  • The following serious adverse reactions are discussed elsewhere in the label: Infections [see Warnings and Precautions (5.1)] Malignancies [see Warnings and Precautions (5.4)] Serious Hypersensitivity Reactions [see Warnings and Precautions (5.5)] Posterior Reversible Encephalopathy Syndrome (PRES) [see Warnings and Precautions (5.6)] Noninfectious Pneumonia [see Warnings and Precautions (5.8)] Most common adverse reactions are: Psoriasis and Psoriatic Arthritis (≥3%): nasopharyngitis, upper respiratory tract infection, headache, and fatigue. (6.1)
  • Crohn's Disease induction (≥3%): vomiting. (6.1)
  • maintenance (≥3%): nasopharyngitis, injection site erythema, vulvovaginal candidiasis/mycotic infection, bronchitis, pruritus, urinary tract infection, and sinusitis. (6.1)
  • Ulcerative Colitis induction (≥3%): nasopharyngitis. (6.1)
  • maintenance (≥3%): nasopharyngitis, headache, abdominal pain, influenza, fever, diarrhea, sinusitis, fatigue, and nausea. (6.1)
  • To report SUSPECTED ADVERSE REACTIONS, contact Janssen Biotech, Inc. at 1-800-526-7736 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Adult Subjects with Plaque Psoriasis The safety data reflect exposure to STELARA in 3117 adult subjects with plaque psoriasis, including 2414 exposed for at least 6 months, 1855 exposed for at least one year, 1653 exposed for at least two years, 1569 exposed for at least three years, 1482 exposed for at least four years and 838 exposed for at least five years.

Table 9 summarizes the adverse reactions that occurred at a rate of at least 1% with higher rates in the STELARA groups during the placebo-controlled period of Ps STUDY 1 and Ps STUDY 2 [see Clinical Studies (14.1)]. Table 9: Adverse Reactions, Reported by ≥1% of Subjects with Plaque Psoriasis and at Higher Rates in the STELARA Groups through Week 12 in Ps STUDY 1 and Ps STUDY 2 STELARA Placebo 45 mg 90 mg Subjects treated 665 664 666 Nasopharyngitis 51 (8%) 56 (8%) 49 (7%) Upper respiratory tract infection 30 (5%) 36 (5%) 28 (4%) Headache 23 (3%) 33 (5%) 32 (5%) Fatigue 14 (2%) 18 (3%) 17 (3%) Back pain 8 (1%) 9 (1%) 14 (2%) Dizziness 8 (1%) 8 (1%) 14 (2%) Pharyngolaryngeal pain 7 (1%) 9 (1%) 12 (2%) Pruritus 9 (1%) 10 (2%) 9 (1%) Injection site erythema 3 (<1%) 6 (1%) 13 (2%) Myalgia 4 (1%) 7 (1%) 8 (1%) Depression 3 (<1%) 8 (1%) 4 (1%) Adverse reactions that occurred at rates less than 1% in the controlled period of Ps STUDIES 1 and 2 through week 12 included: cellulitis, herpes zoster, diverticulitis, and certain injection site reactions (pain, swelling, pruritus, induration, hemorrhage, bruising, and irritation).

One case of PRES occurred during clinical trials in adult subjects with plaque psoriasis [see Warnings and Precautions (5.6)]. Infections In the placebo-controlled period of clinical trials of subjects with plaque psoriasis (average follow-up of 12.6 weeks for subjects receiving placebo and 13.4 weeks for STELARA-treated subjects), 27% of STELARA-treated subjects reported infections (1.39 per patient-years of follow-up) compared with 24% of subjects receiving placebo (1.21 per patient-years of follow-up).

Serious infections occurred in 0.3% of STELARA-treated subjects (0.01 per patient-years of follow-up) and in 0.4% of subjects receiving placebo (0.02 per patient-years of follow-up) [see Warnings and Precautions (5.1)]. In the controlled and non-controlled portions of clinical trials in subjects with plaque psoriasis (median follow-up of 3.2 years), representing 8998 patient-years of exposure, 72.3% of STELARA-treated subjects reported infections (0.87 per patient-years of follow-up).

Serious infections were reported in 2.8% of subjects (0.01 per patient-years of follow-up). Malignancies In the controlled and non-controlled portions of clinical trials in subjects with plaque psoriasis (median follow-up of 3.2 years, representing 8998 patient-years of exposure), 1.7% of STELARA-treated subjects reported malignancies excluding non-melanoma skin cancers (0.60 per hundred patient-years of follow-up).

Non-melanoma skin cancer was reported in 1.5% of STELARA-treated subjects (0.52 per hundred patient-years of follow-up) [see Warnings and Precautions (5.4)]. The most frequently observed malignancies other than non-melanoma skin cancer during the clinical trials were: prostate, melanoma, colorectal and breast. Malignancies other than non-melanoma skin cancer in STELARA-treated subjects during the controlled and uncontrolled portions of trials were similar in type and number to what would be expected in the general U.S. population according to the 1969–2004 SEER database (adjusted for age, gender and race).

Pediatric Subjects with Plaque Psoriasis The safety of STELARA was assessed in two trials of pediatric subjects with moderate to severe plaque psoriasis. Ps STUDY 3 evaluated safety for up to 60 weeks in 110 pediatric subjects 12 to 17 years old. Ps STUDY 4 evaluated safety for up to 56 weeks in 44 pediatric subjects 6 to 11 years old.

The safety profile in pediatric subjects was similar to the safety profile from trials in adults with plaque psoriasis. Psoriatic Arthritis The safety of STELARA was assessed in 927 subjects in two randomized, double-blind, placebo-controlled trials in adults with active psoriatic arthritis (PsA). The overall safety profile of STELARA in subjects with PsA was consistent with the safety profile seen in clinical trials in adult subjects with plaque psoriasis.

A higher incidence of arthralgia, nausea, and dental infections was observed in STELARA-treated subjects when compared with placebo-treated subjects (3% vs. 1% for arthralgia and 3% vs. 1% for nausea; 1% vs. 0.6% for dental infections) in the placebo-controlled portions of the PsA clinical trials. Adult Subjects with Crohn's Disease The safety of STELARA was assessed in 1407 subjects with moderately to severely active Crohn's disease (Crohn's Disease Activity Index [CDAI] greater than or equal to 220 and less than or equal to 450) in three randomized, double-blind, placebo-controlled, parallel-group, multicenter trials.

These 1407 subjects included 40 subjects who received a prior investigational intravenous ustekinumab formulation but were not included in the efficacy analyses. In trials CD-1 and CD-2 there were 470 subjects who received STELARA 6 mg/kg as a weight-based single intravenous induction dose and 466 who received placebo [see Dosage and Administration (2.3)].

Subjects who were responders in either trial CD-1 or CD-2 were randomized to receive a subcutaneous maintenance regimen of either 90 mg STELARA every 8 weeks, or placebo for 44 weeks in trial CD-3. Subjects in these 3 trials may have received other concomitant therapies including aminosalicylates, immunomodulatory agents [azathioprine (AZA), 6-mercaptopurine (6-MP), methotrexate (MTX)], oral corticosteroids (prednisone or budesonide), and/or antibiotics for their Crohn's disease [see Clinical Studies (14.4)].

The overall safety profile of STELARA was consistent with the safety profile seen in the clinical trials in adult subjects with plaque psoriasis and psoriatic arthritis. Common adverse reactions in trials CD-1 and CD-2 and in trial CD-3 are listed in Tables 10 and 11, respectively. Table 10: Common Adverse Reactions Through Week 8 in Trials CD-1 and CD-2 occurring in ≥3% of STELARA-Treated Subjects and Higher Than Subjects Receiving Placebo STELARA Placebo N=466 6 mg/kg Single Intravenous Induction Dose N=470 Vomiting 3% 4% Other less common adverse reactions reported in subjects in trials CD-1 and CD-2 included asthenia (1% vs 0.4%), acne (1% vs 0.4%), and pruritus (2% vs 0.4%).

Table 11: Common Adverse Reactions Through Week 44 in Trial CD-3 occurring in ≥3% of STELARA-Treated Subjects and Higher Than Subjects Receiving Placebo STELARA Placebo N=133 90 mg Subcutaneous Maintenance Dose Every 8 Weeks N=131 Nasopharyngitis 8% 11% Injection site erythema 0 5% Vulvovaginal candidiasis/mycotic infection 1% 5% Bronchitis 3% 5% Pruritus 2% 4% Urinary tract infection 2% 4% Sinusitis 2% 3% Infections In subjects with Crohn's disease, serious or other clinically significant infections included anal abscess, gastroenteritis, and pneumonia. In addition, listeria meningitis and ophthalmic herpes zoster were reported in one subject each [see Warnings and Precautions (5.1)].

Malignancies With up to one year of treatment in the Crohn's disease clinical trials, 0.2% of STELARA-treated subjects (0.36 events per hundred patient-years) and 0.2% of placebo-treated subjects (0.58 events per hundred patient-years) developed non-melanoma skin cancer. Malignancies other than non-melanoma skin cancers occurred in 0.2% of STELARA-treated subjects (0.27 events per hundred patient-years) and in none of the placebo-treated subjects [see Warnings and Precautions (5.4)].

Hypersensitivity Reactions Including Anaphylaxis In CD trials, two subjects reported hypersensitivity reactions following STELARA administration. One subject experienced signs and symptoms consistent with anaphylaxis (tightness of the throat, shortness of breath, and flushing) after a single subcutaneous administration (0.1% of subjects receiving subcutaneous STELARA).

In addition, one subject experienced signs and symptoms consistent with or related to a hypersensitivity reaction (chest discomfort, flushing, urticaria, and increased body temperature) after the initial intravenous STELARA dose (0.08% of subjects receiving intravenous STELARA). These subjects were treated with oral antihistamines or corticosteroids and in both cases symptoms resolved within an hour [see Warnings and Precautions (5.5)].

Pediatric Subjects with Crohn's Disease The safety of STELARA has been studied in 101 pediatric subjects (2 to 17 years of age) with moderately to severely active Crohn's disease and 48 subjects received the recommended maintenance dosage [see Clinical Studies (14.5)]. In general, adverse reactions reported in the clinical trial of pediatric subjects with Crohn's disease were similar to those reported in adult subjects with Crohn's disease in Studies CD-1, CD-2, and CD-3 [see Clinical Studies (14.4)].

Other adverse reactions reported in at least 10% of pediatric subjects were upper respiratory tract infection (13% during induction and 17% during maintenance), COVID-19 (17% during maintenance), and headache (10% during maintenance). One pediatric subject discontinued treatment with STELARA after developing anaphylactic shock within the first two minutes of initiation of the first intravenous infusion and was stabilized with medical intervention [see Warnings and Precautions (5.5)].

Adult Subjects with Ulcerative Colitis The safety of STELARA was evaluated in two randomized, double-blind, placebo-controlled clinical trials (UC-1 [IV induction] and UC-2 [SC maintenance]) in 960 adult subjects with moderately to severely active ulcerative colitis [see Clinical Studies (14.6)]. The overall safety profile of STELARA in subjects with ulcerative colitis was consistent with the safety profile seen across all approved indications.

Adverse reactions reported in at least 3% of STELARA-treated subjects and at a higher rate than placebo were: Induction (UC-1): nasopharyngitis (7% vs 4%). Maintenance (UC-2): nasopharyngitis (24% vs 20%), headache (10% vs 4%), abdominal pain (7% vs 3%), influenza (6% vs 5%), fever (5% vs. 4%), diarrhea (4% vs 1%), sinusitis (4% vs 1%), fatigue (4% vs 2%), and nausea (3% vs 2%).

Infections In subjects with ulcerative colitis, serious or other clinically significant infections included gastroenteritis and pneumonia. In addition, listeriosis and ophthalmic herpes zoster were reported in one subject each [see Warnings and Precautions (5.1)]. Malignancies With up to one year of treatment in the ulcerative colitis clinical trials, 0.4% of STELARA-treated subjects (0.48 events per hundred patient-years) and 0.0% of subjects receiving placebo (0.00 events per hundred patient-years) developed non-melanoma skin cancer.

Malignancies other than non-melanoma skin cancers occurred in 0.5% of STELARA-treated subjects (0.64 events per hundred patient-years) and 0.2% of subjects receiving placebo (0.40 events per hundred patient-years) [see Warnings and Precautions (5.4)]. Pediatric Subjects with Ulcerative Colitis The safety of STELARA was assessed in 112 pediatric subjects (3 to 17 years of age) with moderately to severely active ulcerative colitis and 54 subjects received the recommended maintenance dosage [see Clinical Studies (14.7)].

In general, adverse reactions reported in the clinical trial of pediatric subjects with ulcerative colitis were similar to those reported in adult subjects with ulcerative colitis in Studies UC-1 and UC-2 [see Clinical Studies (14.6)]. One pediatric subject experienced worsening of preexisting peripheral neuropathy during treatment with STELARA, resulting in hospitalization.

6.2 Postmarketing Experience

6.2 Postmarketing Experience The following adverse reactions have been reported during post-approval use of STELARA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to STELARA exposure.

Immune system disorders: Hypersensitivity reactions (e.g., anaphylaxis, angioedema, dyspnea, rash, urticaria), including a fatal case that presented with chest tightness and dyspnea during infusion of the first dose. Some cases of serious hypersensitivity reactions have been reported in patients with a history of alpha-gal syndrome, allergy to mammalian meat or meat products, or anti-alpha-gal IgE.

In most of these cases the reactions occurred at the time of initial administration. Infections and infestations: Lower respiratory tract infection (including opportunistic fungal infections and tuberculosis). Neurological disorders: Posterior Reversible Encephalopathy Syndrome (PRES). Respiratory, thoracic, and mediastinal disorders: Interstitial pneumonia, eosinophilic pneumonia, and cryptogenic organizing pneumonia.

Skin reactions: Pustular psoriasis, erythrodermic psoriasis, hypersensitivity vasculitis.

Adverse reaction frequency tables (US label) US FDA label
Table 9: Adverse Reactions, Reported by ≥1% of Subjects with Plaque Psoriasis and at Higher Rates in the STELARA Groups through Week 12 in Ps STUDY 1 and Ps STUDY 2
STELARA
Placebo45 mg90 mg
Subjects treated665664666
Nasopharyngitis51 (8%)56 (8%)49 (7%)
Upper respiratory tract infection30 (5%)36 (5%)28 (4%)
Headache23 (3%)33 (5%)32 (5%)
Fatigue14 (2%)18 (3%)17 (3%)
Back pain8 (1%)9 (1%)14 (2%)
Dizziness8 (1%)8 (1%)14 (2%)
Pharyngolaryngeal pain7 (1%)9 (1%)12 (2%)
Pruritus9 (1%)10 (2%)9 (1%)
Injection site erythema3 (<1%)6 (1%)13 (2%)
Myalgia4 (1%)7 (1%)8 (1%)
Depression3 (<1%)8 (1%)4 (1%)
Table 10: Common Adverse Reactions Through Week 8 in Trials CD-1 and CD-2 occurring in ≥3% of STELARA-Treated Subjects and Higher Than Subjects Receiving Placebo
STELARA
Placebo N=4666 mg/kg Single Intravenous Induction Dose N=470
Vomiting3%4%
Table 11: Common Adverse Reactions Through Week 44 in Trial CD-3 occurring in ≥3% of STELARA-Treated Subjects and Higher Than Subjects Receiving Placebo
STELARA
Placebo N=13390 mg Subcutaneous Maintenance Dose Every 8 Weeks N=131
Nasopharyngitis8%11%
Injection site erythema05%
Vulvovaginal candidiasis/mycotic infection1%5%
Bronchitis3%5%
Pruritus2%4%
Urinary tract infection2%4%
Sinusitis2%3%

Pregnancy considerations

Pregnancy (US label) US FDA label

8.1 Pregnancy Risk Summary Available data from the Organization of Teratology Information Specialists (OTIS)/MotherToBaby STELARA Pregnancy Registry, published literature and pharmacovigilance in pregnant women have not identified a STELARA-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes (see Data). There are risks to the mother and the fetus associated with inflammatory bowel disease (IBD) in pregnancy.

In animal reproductive and developmental toxicity studies, no adverse developmental effects were observed in offspring after administration of ustekinumab to pregnant monkeys at exposures greater than 100 times the maximum recommended human dose (MRHD). All pregnancies have a background risk of birth defect, loss, or other adverse outcomes.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage of clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Clinical Considerations Disease-associated Maternal and Embryo/Fetal Risk Published data suggest that the risk of adverse pregnancy outcomes in women with IBD is associated with increased disease activity.

Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth. Fetal/Neonatal Adverse Reactions Transport of endogenous IgG antibodies across the placenta increases as pregnancy progresses, and peaks during the third trimester.

Therefore, STELARA may be present in infants exposed in utero. The potential clinical impact of ustekinumab exposure in infants exposed in utero should be considered. Data Human Data An observational pregnancy registry conducted by (OTIS)/MotherToBaby in the U.S. and Canada (enrollment between 2013 and 2019) assessed the risk of major birth defects, pattern of major and minor anomalies in live-born infants, miscarriage, and adverse infant outcomes in women with STELARA exposure.

In the registry study, there were 101 participants and 107 pregnancies with exposure to STELARA (88 prospective; 19 retrospective). Most participants had a primary indication of CD (65.4%) or psoriasis (30.8%). The pregnancy registry did not identify a STELARA-associated risk of major birth defects, pattern of major or minor anomalies, increased risk of miscarriage or adverse infant outcomes.

Methodological limitations of the registry include small sample size, lack of an internal comparison group, a mix of prospective and retrospective reports, and unmeasured confounders. The conclusions from the pregnancy registry were consistent with the published literature and pharmacovigilance. Animal Data Ustekinumab was tested in two embryo-fetal development toxicity studies in cynomolgus monkeys.

No teratogenic or other adverse developmental effects were observed in fetuses from pregnant monkeys that were administered ustekinumab subcutaneously twice weekly or intravenously weekly during the period of organogenesis. Serum concentrations of ustekinumab in pregnant monkeys were greater than 100 times the serum concentration in patients treated subcutaneously with 90 mg of ustekinumab weekly for 4 weeks.

In a combined embryo-fetal development and pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered subcutaneous doses of ustekinumab twice weekly at exposures greater than 100 times the MRHD from the beginning of organogenesis to Day 33 after delivery. Neonatal deaths occurred in the offspring of one monkey administered ustekinumab at 22.5 mg/kg and one monkey dosed at 45 mg/kg.

No ustekinumab-related-effects on functional, morphological, or immunological development were observed in the neonates from birth through six months of age.

Mechanism of action

12.1 Mechanism of Action Ustekinumab is a human IgG1қ monoclonal antibody that binds with specificity to the p40 protein subunit used by both the IL-12 and IL-23 cytokines. IL-12 and IL-23 are naturally occurring cytokines that are involved in inflammatory and immune responses, such as natural killer cell activation and CD4+ T-cell differentiation and activation.

In in vitro models, ustekinumab was shown to disrupt IL-12 and IL-23 mediated signaling and cytokine cascades by disrupting the interaction of these cytokines with a shared cell-surface receptor chain, IL-12Rβ1. The cytokines IL-12 and IL-23 have been implicated as important contributors to the chronic inflammation that is a hallmark of Crohn's disease and ulcerative colitis.

In animal models of colitis, genetic absence or antibody blockade of the p40 subunit of IL-12 and IL-23, the target of ustekinumab, was shown to be protective.

US FDA label

Pharmacodynamics

Pharmacodynamics (US label) US FDA label

12.2 Pharmacodynamics Plaque Psoriasis In a small exploratory trial, a decrease was observed in the expression of mRNA of its molecular targets IL-12 and IL-23 in lesional skin biopsies measured at baseline and up to two weeks post-treatment in subjects with plaque psoriasis. Ulcerative Colitis In both trial UC-1 (induction) and trial UC-2 (maintenance), a positive relationship was observed between exposure and rates of clinical remission, clinical response, and endoscopic improvement.

The response rate approached a plateau at the ustekinumab exposures associated with the recommended dosing regimen for maintenance treatment [see Clinical Studies (14.6)].

Pharmacokinetics

Half-life and elimination (verbatim, US label)

Elimination The mean (±SD) half-life ranged from 14.9 ± 4.6 to 45.6 ± 80.2 days across all trials in subjects with plaque psoriasis following subcutaneous administration.

Population pharmacokinetic analyses showed that the clearance of ustekinumab was 0.19 L/day (95% CI: 0.185, 0.197) in subjects with Crohn's disease and 0.19 L/day (95% CI: 0.179, 0.192) in subjects with ulcerative colitis with an estimated median terminal half-life of approximately 19 days for both IBD (Crohn's disease and ulcerative colitis) populations.

Pharmacokinetics (US label) US FDA label

12.3 Pharmacokinetics Absorption In adult subjects with plaque psoriasis, the median time to reach the maximum serum concentration (T max) was 13.5 days and 7 days, respectively, after a single subcutaneous administration of 45 mg (N=22) and 90 mg (N=24) of ustekinumab. In healthy subjects (N=30), the median T max value (8.5 days) following a single subcutaneous administration of 90 mg of ustekinumab was comparable to that observed in subjects with plaque psoriasis.

Following multiple subcutaneous doses of STELARA in adult subjects with plaque psoriasis, steady-state serum concentrations of ustekinumab were achieved by Week 28. The mean (±SD) steady-state trough serum ustekinumab concentrations were 0.69 ± 0.69 mcg/mL for subjects less than or equal to 100 kg receiving a 45 mg dose and 0.74 ± 0.78 mcg/mL for subjects greater than 100 kg receiving a 90 mg dose.

There was no apparent accumulation in serum ustekinumab concentration over time when given subcutaneously every 12 weeks. Following the recommended intravenous induction dose, mean ±SD peak serum ustekinumab concentration was 125.2 ± 33.6 mcg/mL in subjects with Crohn's disease, and 129.1 ± 27.6 mcg/mL in subjects with ulcerative colitis.

Starting at Week 8, the recommended subcutaneous maintenance dosing of 90 mg ustekinumab was administered every 8 weeks. Steady-state ustekinumab concentration was achieved by the start of the second maintenance dose. There was no apparent accumulation in ustekinumab concentration over time when given subcutaneously every 8 weeks.

Mean ±SD steady-state trough concentration was 2.5 ± 2.1 mcg/mL in subjects with Crohn's disease, and 3.3 ± 2.3 mcg/mL in subjects with ulcerative colitis for 90 mg ustekinumab administered every 8 weeks. Distribution Population pharmacokinetic analyses showed that the volume of distribution of ustekinumab in the central compartment was 2.7 L (95% CI: 2.69, 2.78) in subjects with Crohn's disease and 3.0 L (95% CI: 2.96, 3.07) in subjects with ulcerative colitis.

The total volume of distribution at steady-state was 4.6 L in subjects with Crohn's disease and 4.4 L in subjects with ulcerative colitis. Elimination The mean (±SD) half-life ranged from 14.9 ± 4.6 to 45.6 ± 80.2 days across all trials in subjects with plaque psoriasis following subcutaneous administration. Population pharmacokinetic analyses showed that the clearance of ustekinumab was 0.19 L/day (95% CI: 0.185, 0.197) in subjects with Crohn's disease and 0.19 L/day (95% CI: 0.179, 0.192) in subjects with ulcerative colitis with an estimated median terminal half-life of approximately 19 days for both IBD (Crohn's disease and ulcerative colitis) populations.

These results indicate the pharmacokinetics of ustekinumab were similar between subjects with Crohn's disease and ulcerative colitis. Metabolism The metabolic pathway of ustekinumab has not been characterized. As a human IgG1κ monoclonal antibody, ustekinumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.

Specific Populations Weight When given the same dose, subjects with plaque psoriasis or psoriatic arthritis weighing more than 100 kg had lower median serum ustekinumab concentrations compared with those subjects weighing 100 kg or less. The median trough serum concentrations of ustekinumab in subjects of higher weight (greater than 100 kg) in the 90 mg group were comparable to those in subjects of lower weight (100 kg or less) in the 45 mg group.

Age: Geriatric Population A population pharmacokinetic analysis (N=106/1937 subjects with plaque psoriasis greater than or equal to 65 years old) was performed to evaluate the effect of age on the pharmacokinetics of ustekinumab. There were no apparent changes in pharmacokinetic parameters (clearance and volume of distribution) in subjects older than 65 years old.

Age: Pediatric Population Following multiple recommended doses of STELARA in pediatric subjects 6 years of age and older with plaque psoriasis, steady-state serum concentrations of ustekinumab were achieved by Week 28. At Week 28, the mean ±SD steady-state trough serum ustekinumab concentrations were 0.36 ± 0.26 mcg/mL and 0.54 ± 0.43 mcg/mL, respectively, in pediatric subjects 6 to 11 years of age and pediatric subjects 12 years of age and older.

Overall, the observed steady-state ustekinumab trough concentrations in pediatric subjects with plaque psoriasis were within the range of those observed for adult subjects with plaque psoriasis and adult subjects with PsA after administration of STELARA. The pharmacokinetics of ustekinumab were studied in pediatric subjects with Crohn's disease aged 2 to 17 years and weighing 13 to 88 kg.

There are no clinically significant differences in serum ustekinumab exposure expected between adult patients and pediatric patients with Crohn's disease who receive the recommended dosage [see Dosage and Administration (2.4)]. The pharmacokinetics of ustekinumab were studied in pediatric subjects with ulcerative colitis aged 3 to 17 years and weighing 14 to 80 kg.

There are no clinically significant differences in serum ustekinumab exposures expected between adult patients and pediatric patients aged 2 years and older with ulcerative colitis disease who receive the recommended dosage [see Dosage and Administration (2.6)]. Drug Interaction Studies The effects of IL-12 or IL-23 on the regulation of CYP450 enzymes were evaluated in an in vitro study using human hepatocytes, which showed that IL-12 and/or IL-23 at levels of 10 ng/mL did not alter human CYP450 enzyme activities (CYP1A2, 2B6, 2C9, 2C19, 2D6, or 3A4).

No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate), dextromethorphan (CYP2D6 substrate), or midazolam (CYP3A substrate) were observed when used concomitantly with ustekinumab at the approved recommended dosage in subjects with Crohn's disease [see Drug Interactions (7.2)]. Population pharmacokinetic analyses indicated that the clearance of ustekinumab was not impacted by concomitant MTX, NSAIDs, and oral corticosteroids, or prior exposure to a TNF blocker in subjects with psoriatic arthritis.

In subjects with Crohn's disease and ulcerative colitis, population pharmacokinetic analyses did not indicate changes in ustekinumab clearance with concomitant use of corticosteroids or immunomodulators (AZA, 6-MP, or MTX); and serum ustekinumab concentrations were not impacted by concomitant use of these medications.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Stelara · Janssen Biotech, Inc. [US FDA-approved label, version 49, September 8, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c77a9664-e3bb-4023-b400-127aa53bca2b
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .